The Microbiome Business & Science Briefing
MicrobimeTimes
Reporting on The Latest Microbiome Business & Scientific Developments
TRENDING
From Discovery to Disease Prevention: How the Biose–Siolta Partnership is Advancing a New Generation of Live Biotherapeutics• A pioneering gut bacterium passes Europe’s food-safety review under the EU Novel Food Regulation• Stanford’s AI Designed Bacteriophages: Ushering in the Next Phase in IP Strategy for Phage Companies?• Breathing Engineered Bacteria: A New Approach to Treating Lung Disease• Vedanta Biosciences Secures $60 Million in Funding Ahead of Pivotal Phase 3 Data• Gut fungi may hold the key to treating Asthma worldwide•

Category: Infectious Disease & AMR

Wyss Institute Receives Grant from Cystic Fibrosis Foundation
Infectious Disease & AMR

Wyss Institute Receives Grant from Cystic Fibrosis Foundation

OCT 18, 2018
Vedanta Biosciences Announces Successful Phase 1a/1b Data for Lead, Rationally Defined Bacterial Consortium Product Candidate
Infectious Disease & AMR

Vedanta Biosciences Announces Successful Phase 1a/1b Data for Lead, Rationally Defined Bacterial Consortium Product Candidate

OCT 4, 2018
Research Study Demonstrates a Role for Nasal Microbiota in the Host Response to Viral Respiratory Infection
Infectious Disease & AMR

Research Study Demonstrates a Role for Nasal Microbiota in the Host Response to Viral Respiratory Infection

SEP 28, 2018
Scientific Analysis Shows Probiotic Use is Associated with Fewer Antibiotic Prescriptions
Editor's Choice

Scientific Analysis Shows Probiotic Use is Associated with Fewer Antibiotic Prescriptions

SEP 19, 2018
Oragenics, Inc. and Texas A&M University System Granted U.S. Patent for Lantibiotic MU1140
Infectious Disease & AMR

Oragenics, Inc. and Texas A&M University System Granted U.S. Patent for Lantibiotic MU1140

MAY 24, 2018
Dutch Biotech Micreos ‘Alternative to Antibiotics’ Wins Ideas From Europe Finals
Infectious Disease & AMR

Dutch Biotech Micreos ‘Alternative to Antibiotics’ Wins Ideas From Europe Finals

APR 26, 2018
New initiative in the fight against antibiotic resistance
Infectious Disease & AMR

New initiative in the fight against antibiotic resistance

APR 26, 2018
Synthetic Biologics Provides Update on Development of SYN-004 (ribaxamase), for the Prevention of C. difficile Infection
Infectious Disease & AMR

Synthetic Biologics Provides Update on Development of SYN-004 (ribaxamase), for the Prevention of C. difficile Infection

APR 23, 2018